2018
DOI: 10.1016/j.ijbiomac.2018.05.147
|View full text |Cite
|
Sign up to set email alerts
|

Characterization, sulfated modification and bioactivity of a novel polysaccharide from Millettia dielsiana

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
11
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 27 publications
(12 citation statements)
references
References 40 publications
1
11
0
Order By: Relevance
“…Rats treated with Sinomenium acutum have a lower level of inflammatory parameters, such as tumor necrosis factor- α (TNF- α ) and prostaglandin-E2 (PG-E2) [ 14 ]. Millettia dielsiana is a TCM to treat RA and gynecological diseases used as antioxidant, immunomodulatory, and anticoagulant agents [ 15 ]. It can help RA patients relieve muscle aches and pains.…”
Section: Discussionmentioning
confidence: 99%
“…Rats treated with Sinomenium acutum have a lower level of inflammatory parameters, such as tumor necrosis factor- α (TNF- α ) and prostaglandin-E2 (PG-E2) [ 14 ]. Millettia dielsiana is a TCM to treat RA and gynecological diseases used as antioxidant, immunomodulatory, and anticoagulant agents [ 15 ]. It can help RA patients relieve muscle aches and pains.…”
Section: Discussionmentioning
confidence: 99%
“…For antioxidant testing in vivo, we found that MZPS-2 had a remarkable ability to scavenge free radicals (P < 0:01). For anti-inflammation testing in vivo, the results , and 50 μg/mL, respectively); IV, V, and VI: three MPS-2-treated groups (10,25, and 50 μg/mL, respectively). * P < 0:05, * * P < 0:01 versus MC; ## P < 0:01 versus VC; a P < 0:05 versus the other group.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, MZPS-2 could potentially be used as a new zinc supplement, which might have a beneficial effect during the treatment of inflammation or oxidative stress caused by zinc deficiency. Shandong Academy of Sciences (2018QN0028, 2019QN002), Technology Development Foundation of (10,25, and 50 μg/mL, respectively); IV, V, and VI: three MPS-2-treated groups (10,25, and 50 μg/mL, respectively). * P < 0:05, * * P < 0:01 versus MC; ## P < 0:01 versus VC.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations